U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C30H27N5O.2CH4O3S.H2O
Molecular Weight 683.795
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-833923 DIMESYLATE MONOHYDRATE

SMILES

O.CS(O)(=O)=O.CS(O)(=O)=O.CNCC1=CC=C(C)C(NC(=O)C2=CC=C(NC3=NC4=C(C=CC=C4)C(=N3)C5=CC=CC=C5)C=C2)=C1

InChI

InChIKey=UYMWHMMVNCGRHJ-UHFFFAOYSA-N
InChI=1S/C30H27N5O.2CH4O3S.H2O/c1-20-12-13-21(19-31-2)18-27(20)33-29(36)23-14-16-24(17-15-23)32-30-34-26-11-7-6-10-25(26)28(35-30)22-8-4-3-5-9-22;2*1-5(2,3)4;/h3-18,31H,19H2,1-2H3,(H,33,36)(H,32,34,35);2*1H3,(H,2,3,4);1H2

HIDE SMILES / InChI

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C30H27N5O
Molecular Weight 473.5683
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula CH4O3S
Molecular Weight 96.106
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24105601 | http://drugprofiles.informa.com/drug_profiles/14075-bms-833923

BMS-833923 was discovered by Exelixis and was out-licensed to Bristol-Myers Squibb. BMS-833923 is an orally bioavailable Smoothened antagonist. BMS-833923 reduces hedgehog pathway activity, decreases cell proliferation and induces apoptosis via the intrinsic pathway in esophageal adenocarcinoma (EAC) cell lines. BMS-833923 dose-dependently affects canonical and prostate hedgehog signature gene transcription in vitro. BMS-833923 is in phase II clinical trials for the treatment of chronic myeloid leukaemia.

Originator

Curator's Comment: BMS-833923 was discovered by Exelixis and was out-licensed to Bristol-Myers Squibb. # Exelixis

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
21.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Emerging treatments and signaling pathway inhibitors.
2011 Dec
Smoothened inhibition leads to decreased proliferation and induces apoptosis in esophageal adenocarcinoma cells.
2013 Aug
Hedgehog signaling is active in human prostate cancer stroma and regulates proliferation and differentiation of adjacent epithelium.
2013 Dec
Patents

Sample Use Guides

Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
Route of Administration: Oral
BMS-833923 (10 uM) decreased cell proliferation of cholangiocellular carcinoma cell line (EGI-1) up to 89.4% compared to the control.
Substance Class Chemical
Created
by admin
on Sat Dec 16 04:54:37 UTC 2023
Edited
by admin
on Sat Dec 16 04:54:37 UTC 2023
Record UNII
483ONS63WN
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-833923 DIMESYLATE MONOHYDRATE
Code English
N-(2-METHYL-5-((METHYL AMINO) METHYL) PHENYL)-4-(4-PHENYLQUINAZOLIN-2-YLAMINO) BENZAMIDE BISMESYLATE MONOHYDRATE
Systematic Name English
Code System Code Type Description
NCI_THESAURUS
C77861
Created by admin on Sat Dec 16 04:54:37 UTC 2023 , Edited by admin on Sat Dec 16 04:54:37 UTC 2023
PRIMARY
SMS_ID
100000174998
Created by admin on Sat Dec 16 04:54:37 UTC 2023 , Edited by admin on Sat Dec 16 04:54:37 UTC 2023
PRIMARY
ChEMBL
CHEMBL3545403
Created by admin on Sat Dec 16 04:54:37 UTC 2023 , Edited by admin on Sat Dec 16 04:54:37 UTC 2023
PRIMARY
PUBCHEM
162623676
Created by admin on Sat Dec 16 04:54:37 UTC 2023 , Edited by admin on Sat Dec 16 04:54:37 UTC 2023
PRIMARY
FDA UNII
483ONS63WN
Created by admin on Sat Dec 16 04:54:37 UTC 2023 , Edited by admin on Sat Dec 16 04:54:37 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY